Skip to content
To the full analysis

Intco Medical Technology Stock: Growth

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

Intco Medical Technology reported $1.49B in revenue for fiscal 2025, up 4.2% on the prior year, down 6.4% a year on average over up to five years. That makes three years of growth in a row.

Daily figure as of 20 Nov 2026

Revenue (Annual rate)
24.5%
per year from 2013 to 2025, per share 16.6%
Earnings (Annual rate)
46.1%
per year from 2013 to 2025, per share 36.7%
Free cash flow (Annual rate)
no data

Growth per Year by Period

What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.

since 2020since 2015since 2013
Revenue−6.4%25.8%24.5%
Revenue per share−16.7%18.4%16.6%
Earnings−32.1%31.7%46.1%
Earnings per share−33.6%23.6%36.7%
Free cash flowno datano datano data
Free cash flow per shareno datano datano data

Growth Over Time

Revenue is 38.9% below its high of $2.44B in 2021. Since 2015 earnings grew faster than revenue, 31.7% against 25.8% a year, because the net margin rose from 6.4% to 10.2%. Intco Medical Technology has made a profit in every fiscal year since 2013. In the quarter to 30 Sep 2026 revenue grew 47.7% on the prior year quarter, after an average of 20.6% in the four quarters before.

Fiscal Years at a Glance

How Revenue and Earnings Grow

  • Revenue
  • Earnings
  • Free cash flow
Figures as a table
YearRevenueEarningsFree cash flow
2013$106.99M$1.6M$868.47K
2014$132.71M$4.78M$4.16M
2015$149.7M$9.63M−$10.21M
2016$177.47M$12.91M−$20.53M
2017$262.57M$21.76M$5.29M
2018$283.88M$26.9M−$18.42M
2019$312.44M$26.75M−$31.03M
2020$2.08B$1.05B$855.25M
2021$2.44B$1.11B$485.47M
2022$992.07M$94.36M−$97.46M
2023$1.04B$57.45M−$140.44M
2024$1.43B$219.82M−$106.56M
2025$1.49B$151.6M−$103.46M

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.